{"filings":[{"id":94572,"accession_number":"0001672688-26-000086","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Absci completes all SAD cohorts of ABS-201, initiates MAD; Q1 net loss $29.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Successfully dosed all four SAD cohorts of ABS-201 Phase 1/2a; well-tolerated with favorable safety.","Initiated MAD dosing in AGA participants; preliminary PK supports 2-3 injections over six months.","Expanded pipeline with ABS-202, a novel anti-PRLR antibody for undisclosed I&I indication.","Q1 revenue $0.2M, net loss $29.6M; cash $125.7M sufficient into first half of 2028.","Anticipates reporting preliminary safety, tolerability, PK data in Q2 2026; proof-of-concept in H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":215000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107056,"accession_number":"0001672688-26-000066","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Absci reports Q4 net loss $29.6M, advances ABS-201 trial, appoints new CMO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dosed first three cohorts in SAD portion of Phase 1/2a HEADLINE trial for ABS-201; well-tolerated with favorable emerging safety.","Net loss Q4 2025 $29.6M vs $29.0M prior year; full year net loss $115.2M vs $103.1M.","Cash, equivalents, and marketable securities $144.3M as of Dec 31, 2025; sufficient to fund operations into first half 2028.","Appointed Ransi Somaratne, M.D. (former Vertex SVP) as Chief Medical Officer to lead clinical strategy.","Interim proof-of-concept data for ABS-201 expected H2 2026; Phase 2 endometriosis trial initiation planned Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107055,"accession_number":"0001672688-26-000047","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Absci appoints Ransi Somaratne as CMO; Chief Innovation Officer Andreas Busch to retire","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ransi Somaratne, formerly SVP Clinical Development at Vertex, appointed CMO effective March 3, 2026.","Andreas Busch, Chief Innovation Officer, will retire March 31, 2026 and serve as scientific advisor for 2 years.","Busch receives $25,500 annual retainer plus grants of 22,800 stock options and 5,800 RSUs under the 2021 Plan.","Busch's vested options (2,489,290 shares) extended up to 3 months post-advisory termination; unvested options cancelled.","Amended director and officer indemnification agreements adopted March 6, 2026, enhancing change-in-control and good faith provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107054,"accession_number":"0001672688-26-000003","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Absci to Present Business Update at 44th Annual J.P. Morgan Healthcare Conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Absci will present a business update at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.","The presentation slides are filed as Exhibit 99.1 to this Form 8-K.","The slides are available in the 'Events and Presentations' section of Absci's investor relations website at investors.absci.com.","The Form 8-K was signed by CEO Sean McClain on January 14, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123395,"accession_number":"0001672688-25-000082","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Absci Reports Q3 2025 Results, Advances ABS-201 and ABS-101 Programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported interim Phase 1 data for ABS-101 (anti-TL1A) showing extended half-life with no serious adverse events.","Accelerated initiation of Phase 1/2a trial for ABS-201 in androgenetic alopecia to December 2025.","Expanding ABS-201 strategy to endometriosis, targeting Phase 2 start in Q4 2026 and proof-of-concept in H2 2027.","Cash, cash equivalents, and marketable securities totaled $152.5 million as of Sept 30, 2025, funding operations into H1 2028.","Net loss was $28.7 million for Q3 2025, compared to $27.4 million in Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":2150000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123394,"accession_number":"0001672688-25-000076","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Absci resolves Totient merger milestone payments; receives $8.7M, pays $7.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Executed Letter Agreement with SBGH to distribute $16.3M escrow funds from 2021 Totient merger.","Absci receives $8.7M of Milestone Consideration; former Totient stockholders get $7.6M.","Agreement fully satisfies all milestone payment obligations under the Merger Agreement.","Escrow Agreement will terminate after disbursement within 5 business days.","Parties enter mutual release; no further payments owed by Absci."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140059,"accession_number":"0001628280-25-039878","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Absci Q2 net loss $30.6M; raises $64M in July extending runway to H1 2028; Almirall collaboration expands","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $30.6M in Q2 2025 (vs $24.8M in Q2 2024); revenue $0.6M (vs $1.3M).","Raised $64M ($50M public offering + $14M ATM) in July 2025; cash+investments $117.5M at June 30; runway into H1 2028.","Expanded Almirall collaboration: second target elected for dermatology; up to $650M in potential milestones across two programs.","ABS-101 Phase 1 interim data expected H2 2025; ABS-201 on track for Phase 1/2a start early 2026 with efficacy readout H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":1772000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140056,"accession_number":"0001628280-25-039959","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K/A","filed_at":"2025-08-12T23:59:59+00:00","items":["9.01","2.02","8.01"],"status":"ready","headline":"Absci Q2 2025 net loss $30.6M; raises $64M in July; Almirall collaboration expands","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue $0.6M (down from $1.3M YoY); net loss $30.6M vs $24.8M prior year.","Cash, equivalents, and ST investments $117.5M at June 30; raised ~$64M in July, extending runway into H1 2028.","Expanded Almirall AI drug discovery collaboration: second target elected, potential up to $650M in milestones across two programs.","ABS-101 (anti-TL1A) Phase 1 interim readout expected H2 2025; ABS-201 (anti-PRLR) Phase 1/2a start early 2026.","AMD strategic collaboration ongoing with $20M equity investment in Jan 2025; platform scaling using AMD Instinct accelerators."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":1772000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140058,"accession_number":"0001193125-25-165466","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Absci prices $50M public offering of 16.67M shares at $3.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 16,670,000 shares at $3.00 per share; gross proceeds ~$50M.","Net proceeds estimated at ~$46.7M (or ~$53.7M if underwriters' option exercised in full).","Proceeds to fund internal programs, Integrated Drug Creation platform, and general corporate purposes.","Underwriters: Morgan Stanley, J.P. Morgan, Jefferies, TD Securities; expected close July 28, 2025.","Offer made under effective shelf registration statement on Form S-3 (File No. 333-267043)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140057,"accession_number":"0001628280-25-034544","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Absci appoints Mary Szela to Board effective July 7, 2025; grants 178,400 share option","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mary Szela appointed as Class III director; board expanded from six to seven members.","Receives initial option grant for 178,400 shares at closing price on grant date, vesting monthly over three years.","Will receive $40,000 annual cash retainer under Non-Employee Director Compensation Policy.","Szela currently serves as CEO, President and Director of Trisalus Life Sciences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157706,"accession_number":"0001628280-25-030953","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Absci stockholders elect van Houten and McGinnis to board, ratify EY as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Frans van Houten elected with 51.4M votes for, 15.7M withheld, 26.1M broker non-votes.","Karen McGinnis elected with 66.6M votes for, 0.55M withheld, same broker non-votes.","Ernst & Young ratified as auditor for FY 2025 with 92.8M for, 211k against, 208k abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157705,"accession_number":"0001628280-25-025075","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Absci starts Phase 1 dosing for ABS-101; Q1 net loss $26.3M, cash into H1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Initiated dosing in first-in-human Phase 1 study of ABS-101 (anti-TL1A); interim data expected H2 2025.","ABS-201 NHP data show extended half-life and >90% subcutaneous bioavailability; Phase 1 start targeted early 2026.","Q1 2025 revenue $1.2M (up from $0.9M YoY); net loss $26.3M vs $22.0M; R&D spending rose to $16.4M.","Cash, equivalents, and short-term investments of $134.0M sufficient to fund operations into first half of 2027.","Company expects to sign one or more new partnerships, including with a large pharma, in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":1179000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157704,"accession_number":"0001628280-25-020260","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Absci director Amrit Nagpal resigns from board effective April 25, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amrit Nagpal resigned from Absci's Board of Directors and all committees effective April 25, 2025.","Resignation not due to any disagreement with the Company on operations, policies, or practices.","No replacement for the vacant board seat has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176073,"accession_number":"0001628280-25-013455","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Absci Q4 revenue $0.7M, net loss $29M; pipeline advances and AMD collaboration","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $0.7M (vs $0.3M YoY); net loss $29.0M vs $23.5M.","Cash & investments $112.4M; sufficient into H1 2027; gross cash burn ~$72M in FY2024.","ABS-101 anti-TL1A to enter Phase 1 in H1 2025; interim data expected H2 2025.","AMD strategic collaboration includes $20M equity investment; AI drug discovery workloads.","Expects to sign one or more drug creation partnerships in 2025, including with Large Pharma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176072,"accession_number":"0001628280-25-001612","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Absci announces J.P. Morgan Healthcare Conference presentation; slides contain no new business data","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation at 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025.","Exhibit 99.1 is only a title slide and disclaimer; no financial or operational updates disclosed.","No changes to guidance, pipeline, or financial position provided in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192986,"accession_number":"0001628280-24-046856","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Absci Q3 revenue $1.7M, net loss $27.4M; achieves AstraZeneca milestone, lowers 2024 cash burn guidance to ~$75M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.7M (up from $0.7M YoY); net loss $27.4M vs $22.0M; cash $127.1M at Sept 30, 2024.","First milestone achieved under AstraZeneca AI antibody collaboration; entered Twist Bioscience partnership for novel antibody design.","Gross cash use expected ~$75M for FY2024, below prior guidance of ~$80M; cash runway into first half 2027.","ABS-101 on track for Phase 1 initiation H1 2025 with interim data H2 2025; ABS-201 candidate selection expected H2 2024.","R&D expenses $18.0M (up from $11.0M) driven by IND-enabling studies for ABS-101; SG&A $9.3M (down from $9.5M)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":3869000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209360,"accession_number":"0001628280-24-039225","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Absci completes first milestone in AstraZeneca oncology collaboration; AI-designed antibodies delivered","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Absci delivered AI-designed antibody sequences to AstraZeneca, fulfilling first milestone under December 2023 collaboration.","AstraZeneca elected to advance sequences into AI-lead optimization phase.","Collaboration combines Absci's Integrated Drug Creation platform with AstraZeneca's oncology expertise.","Goal: accelerate discovery of a potential new cancer treatment candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209359,"accession_number":"0001628280-24-037183","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Absci Q2 2024: revenue $1.3M, net loss $24.8M; ABS-101 half-life 2-3x; MSK collab","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $1.3M (down from $3.4M YoY); net loss $24.8M vs $41.7M (incl. $21.3M non-cash impairment in prior year).","Cash, cash equivalents and short-term investments $145.2M; expects runway into H1 2027.","ABS-101 NHP data: 2-3x extended half-life vs clinical anti-TL1A antibodies; 200 mg/mL formulation supports subcutaneous.","Entered collaboration with Memorial Sloan Kettering to co-develop up to 6 novel oncology therapeutics using generative AI.","Anticipates Phase 1 start for ABS-101 in early 2025; interim data readout expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":2168000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227355,"accession_number":"0001628280-24-028285","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Absci stockholders elect three Class III directors and ratify EY as auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Sean McClain, Amrit Nagpal, and Joseph Sirosh elected Class III directors for terms until 2027 annual meeting.","McClain received 65,972,631 votes for, 311,416 withhold; Nagpal 52,937,845 for, 13,346,202 withhold.","Sirosh received 66,155,521 for, 128,526 withhold; broker non-votes 27,170,637 on each director.","Ratification of Ernst & Young as independent auditor for FY 2024 approved with 93,309,150 for, 29,588 against, 115,946 abstain.","No other matters were submitted to or voted on at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227354,"accession_number":"0001628280-24-023060","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Absci reports Q1 net loss $22M, cash $161.5M; advances ABS-101 to IND-enabling studies","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $0.9M (down from $1.3M YoY); net loss $22.0M vs $23.4M prior year.","Cash, equivalents & short-term investments $161.5M as of Mar 31, 2024, up from $97.7M Dec 31, 2023; includes $86.4M gross from March offering.","IND-enabling studies initiated for ABS-101 (anti-TL1A antibody) in Feb 2024; expects Phase 1 start early 2025, interim data H2 2025.","Anticipates selecting development candidate for ABS-201 (dermatology) in H2 2024; ABS-301 (immuno-oncology) advancing.","Expects to sign at least four drug creation partnerships in 2024; cash runway into H1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":898000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246226,"accession_number":"0001628280-24-012365","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Absci Q4 net loss $23.5M; initiates IND-enabling for ABS-101; AstraZeneca deal up to $247M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY23 net loss $110.6M, revenue $5.7M flat YoY; Q4 net loss $23.5M.","Initiated IND-enabling for ABS-101 (anti-TL1A); IND expected Q1 2025.","Signed AstraZeneca collaboration for up to $247M in milestones plus royalties.","Raised $86.4M in common stock offering; cash $97.7M at Dec 31; runway into H1 2027.","Appointed Sir Menelas Pangalos to Board and co-chair of Scientific Advisory Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}